ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Takeda taps Wave for antisense compounds

by Ryan Cross
February 26, 2018 | APPEARED IN VOLUME 96, ISSUE 9

Takeda Pharmaceutical is partnering with Wave Life Sciences to develop antisense nucleic acid therapies to treat neurological conditions such as Huntington’s disease and amyotrophic lateral sclerosis. Takeda will pay $110 million in cash to Wave, purchase $60 million of Wave’s shares, and provide $60 million or more in research funding over four years. Wave’s oligonucleotides are designed to block the production of proteins that cause disease. The Harvard chemist and serial entrepreneur Gregory Verdine was one of Wave’s cofounders.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment